Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges

The Direct Oral Anticoagulants (DOACs) represent a new generation of antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or activated factor X (FXa). Around the globe, their use is progressively rising, as these new agents replace the historical anticoagulants (h...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Current drug metabolism Ročník 18; číslo 7; s. 598
Hlavní autori: Favaloro, Emmanuel J, Pasalic, Leonardo, Curnow, Jennifer, Lippi, Giuseppe
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Netherlands 01.07.2017
Predmet:
Administration, Oral
Anticoagulants - pharmacology
Anticoagulants - therapeutic use
Blood Coagulation Tests
Drug Monitoring
Humans
Laboratories
NOACs
DOACs
Non-vitamin K antagonist oral anticoagulants
dabigatran
Direct oral anticoagulants
rivaroxaban
monitoring
apixaban
edoxaban
measurement
betrixaban
ISSN:1875-5453, 1875-5453
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract The Direct Oral Anticoagulants (DOACs) represent a new generation of antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or activated factor X (FXa). Around the globe, their use is progressively rising, as these new agents replace the historical anticoagulants (heparin and vitamin K antagonists including warfarin) for various clinical conditions in medical practice. Other acronyms used to designate DOACs include TSOAC (target specific oral anticoagulants) and NOAC (novel; or non-vitamin K antagonist oral anticoagulants). Currently available DOACS include dabigatran (FIIa inhibitor), along with rivaroxaban, apixaban, edoxaban and betrixaban (FXa inhibitors). This narrative review aims to briefly summarise the evidence concerning utility of different laboratory assays for qualitative or quantitative assessment of DOACs, emphasizing the difference between 'drug monitoring' and 'drug measurement' and ultimately discussing advantages and limitations of these processes. Recently, the dogma that these innovative anticoagulant agents will not necessitate laboratory testing has been challenged with the recognition that assessment of drug concentration or activity may be required in some circumstances, although this does not immediately translate to the concept of 'drug monitoring'.
AbstractList The Direct Oral Anticoagulants (DOACs) represent a new generation of antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or activated factor X (FXa). Around the globe, their use is progressively rising, as these new agents replace the historical anticoagulants (heparin and vitamin K antagonists including warfarin) for various clinical conditions in medical practice. Other acronyms used to designate DOACs include TSOAC (target specific oral anticoagulants) and NOAC (novel; or non-vitamin K antagonist oral anticoagulants). Currently available DOACS include dabigatran (FIIa inhibitor), along with rivaroxaban, apixaban, edoxaban and betrixaban (FXa inhibitors). This narrative review aims to briefly summarise the evidence concerning utility of different laboratory assays for qualitative or quantitative assessment of DOACs, emphasizing the difference between 'drug monitoring' and 'drug measurement' and ultimately discussing advantages and limitations of these processes. Recently, the dogma that these innovative anticoagulant agents will not necessitate laboratory testing has been challenged with the recognition that assessment of drug concentration or activity may be required in some circumstances, although this does not immediately translate to the concept of 'drug monitoring'.
The Direct Oral Anticoagulants (DOACs) represent a new generation of antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or activated factor X (FXa). Around the globe, their use is progressively rising, as these new agents replace the historical anticoagulants (heparin and vitamin K antagonists including warfarin) for various clinical conditions in medical practice. Other acronyms used to designate DOACs include TSOAC (target specific oral anticoagulants) and NOAC (novel; or non-vitamin K antagonist oral anticoagulants). Currently available DOACS include dabigatran (FIIa inhibitor), along with rivaroxaban, apixaban, edoxaban and betrixaban (FXa inhibitors).BACKGROUNDThe Direct Oral Anticoagulants (DOACs) represent a new generation of antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or activated factor X (FXa). Around the globe, their use is progressively rising, as these new agents replace the historical anticoagulants (heparin and vitamin K antagonists including warfarin) for various clinical conditions in medical practice. Other acronyms used to designate DOACs include TSOAC (target specific oral anticoagulants) and NOAC (novel; or non-vitamin K antagonist oral anticoagulants). Currently available DOACS include dabigatran (FIIa inhibitor), along with rivaroxaban, apixaban, edoxaban and betrixaban (FXa inhibitors).This narrative review aims to briefly summarise the evidence concerning utility of different laboratory assays for qualitative or quantitative assessment of DOACs, emphasizing the difference between 'drug monitoring' and 'drug measurement' and ultimately discussing advantages and limitations of these processes.OBJECTIVEThis narrative review aims to briefly summarise the evidence concerning utility of different laboratory assays for qualitative or quantitative assessment of DOACs, emphasizing the difference between 'drug monitoring' and 'drug measurement' and ultimately discussing advantages and limitations of these processes.Recently, the dogma that these innovative anticoagulant agents will not necessitate laboratory testing has been challenged with the recognition that assessment of drug concentration or activity may be required in some circumstances, although this does not immediately translate to the concept of 'drug monitoring'.RESULTS AND CONCLUSIONRecently, the dogma that these innovative anticoagulant agents will not necessitate laboratory testing has been challenged with the recognition that assessment of drug concentration or activity may be required in some circumstances, although this does not immediately translate to the concept of 'drug monitoring'.
Author Favaloro, Emmanuel J
Pasalic, Leonardo
Lippi, Giuseppe
Curnow, Jennifer
Author_xml – sequence: 1
  givenname: Emmanuel J
  surname: Favaloro
  fullname: Favaloro, Emmanuel J
  organization: Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW 2145. Australia
– sequence: 2
  givenname: Leonardo
  surname: Pasalic
  fullname: Pasalic, Leonardo
  organization: Pathology West, NSW Health Pathology. Australia
– sequence: 3
  givenname: Jennifer
  surname: Curnow
  fullname: Curnow, Jennifer
  organization: Pathology West, NSW Health Pathology. Australia
– sequence: 4
  givenname: Giuseppe
  surname: Lippi
  fullname: Lippi, Giuseppe
  organization: Pathology West, NSW Health Pathology. Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28413976$$D View this record in MEDLINE/PubMed
BookMark eNpNkF9LwzAUxYNMdE6_gsS3CU6bNM0f38rmVNjYiz6PNL2dgTaZSSrs21txgk_3cPlxOOdcoJHzDhC6Idk9JYI9kFwqmmWUSM45ERkjglCW5cUJGhMpilnBinz0T5-hcyoZyZXgY3RY6coHnXw44LV3dhDW7bAPeA069gE6cAn7Bi9sAJPwJugWly5Z4_Wub7VLEU8Xm3Iebx9xWX8ND72DeIdXtrNJJ-tdxNrVeNmnwQ3PP3TbghuQS3Ta6DbC1fFO0Pvy6W3-Mlttnl_n5WpWMZGlGQGlCAfZ0KqpDGO8-ilslKmlqqERoEzFRSFUo1jFoOEDl4mGMpoXuTE1naDpr-8--M8eYtp2Nhpoh-zg-7glUkrFi2GxAb0-on3VQb3dB9vpcNj-zUW_Acfobqo
CitedBy_id crossref_primary_10_1186_s13584_019_0285_9
crossref_primary_10_1097_WNP_0000000000000643
crossref_primary_10_3389_fphar_2021_702057
crossref_primary_10_3389_fphar_2018_00491
crossref_primary_10_1055_s_0041_1726372
crossref_primary_10_1111_imj_13995
crossref_primary_10_1515_cclm_2019_1160
crossref_primary_10_1515_cclm_2025_0775
crossref_primary_10_1055_s_0044_1782196
crossref_primary_10_1080_14779072_2020_1823218
crossref_primary_10_1515_cclm_2018_0174
crossref_primary_10_1515_cclm_2018_1041
crossref_primary_10_1515_dx_2018_0099
crossref_primary_10_1016_j_thromres_2019_05_013
crossref_primary_10_1016_j_medcle_2018_07_005
crossref_primary_10_1055_a_1753_2748
crossref_primary_10_1213_ANE_0000000000006756
crossref_primary_10_1002_ajh_25669
crossref_primary_10_1097_FJC_0000000000001038
crossref_primary_10_3390_diagnostics14171991
crossref_primary_10_2478_acph_2022_0034
crossref_primary_10_1055_s_0041_1729856
crossref_primary_10_1016_j_pathol_2018_11_008
crossref_primary_10_1177_10760296241228239
crossref_primary_10_1177_10760296241241524
crossref_primary_10_1016_j_cca_2018_08_017
crossref_primary_10_2174_1573412914666180409145403
crossref_primary_10_3390_jcm11216369
crossref_primary_10_1093_ajcp_aqab004
crossref_primary_10_1111_hae_13587
crossref_primary_10_1515_jbcpp_2021_0079
ContentType Journal Article
Copyright Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Copyright_xml – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.2174/1389200218666170417124035
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 1875-5453
ExternalDocumentID 28413976
Genre Journal Article
Review
GroupedDBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-b470t-1e9916e8f2bfbc446b1389c9cd89def7e9cb67579f94b4ef62bf07f242353ccd2
IEDL.DBID 7X8
ISICitedReferencesCount 43
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000409908500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1875-5453
IngestDate Fri Jul 11 09:20:05 EDT 2025
Thu Jan 02 23:11:17 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords NOACs
DOACs
Non-vitamin K antagonist oral anticoagulants
dabigatran
Direct oral anticoagulants
rivaroxaban
monitoring
apixaban
edoxaban
measurement
betrixaban
Language English
License Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b470t-1e9916e8f2bfbc446b1389c9cd89def7e9cb67579f94b4ef62bf07f242353ccd2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 28413976
PQID 1888965403
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1888965403
pubmed_primary_28413976
PublicationCentury 2000
PublicationDate 2017-07-01
PublicationDateYYYYMMDD 2017-07-01
PublicationDate_xml – month: 07
  year: 2017
  text: 2017-07-01
  day: 01
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Current drug metabolism
PublicationTitleAlternate Curr Drug Metab
PublicationYear 2017
Score 2.3843343
SecondaryResourceType review_article
Snippet The Direct Oral Anticoagulants (DOACs) represent a new generation of antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa)...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 598
SubjectTerms Administration, Oral
Anticoagulants - pharmacology
Anticoagulants - therapeutic use
Blood Coagulation Tests
Drug Monitoring
Humans
Laboratories
Title Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges
URI https://www.ncbi.nlm.nih.gov/pubmed/28413976
https://www.proquest.com/docview/1888965403
Volume 18
WOSCitedRecordID wos000409908500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjxga_6YgseFFzMe7NeRIrFg609KPQWkn2Al6QmUei_d2Y3pSdB8JJTsoSZ2ZlvZnbnI-QqAiNJVGSYkFKwCPTA0liGsPF4nio_SWVgLNkEn0zS2UxMu4Jb0x2rXPpE66hVJbFGfudDqiYSwBfhw_yTIWsUdlc7Co110gsByqBV85m9_QYwnAE4CLfIAE87A-6-w5Zc4EiYEhxDHvncx2l08e_g0gaZ0e5_f2-P7HTwkj46e9gna7o8IIsXp-mqXlC3h7GYR6uajlcVQloZ6vwffa1xiRKWqHJkqi_bhl5DEjlsbu6ppWFuwQs1t9TejnIlP5qXio7sgBI6XBK0NIfkffT0NnxmHeUCKyLutczXiBd1aoLCFBJSxQKlJoVUqVDacC1kASkGF0ZERaRNAu953CAoi0MpVXBENsqq1CeExkaEovAMT3IvUpCIiTgAtMUVgAwjVNEng6UkMzBp7FPkpa6-mmwlyz45durI5m72RgbRFDFrcvqHr8_IdoBB2B6uPSc9AxtaX5BN-d1-NPWltRV4TqbjHxi9yZ0
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Laboratory+Monitoring+or+Measurement+of+Direct+Oral+Anticoagulants+%28DOACs%29%3A+Advantages%2C+Limitations+and+Future+Challenges&rft.jtitle=Current+drug+metabolism&rft.au=Favaloro%2C+Emmanuel+J&rft.au=Pasalic%2C+Leonardo&rft.au=Curnow%2C+Jennifer&rft.au=Lippi%2C+Giuseppe&rft.date=2017-07-01&rft.eissn=1875-5453&rft.volume=18&rft.issue=7&rft.spage=598&rft_id=info:doi/10.2174%2F1389200218666170417124035&rft_id=info%3Apmid%2F28413976&rft_id=info%3Apmid%2F28413976&rft.externalDocID=28413976
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1875-5453&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1875-5453&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1875-5453&client=summon